NXTCL Stock Overview
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NextCell Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.31 |
| 52 Week High | kr6.44 |
| 52 Week Low | kr1.20 |
| Beta | 0.71 |
| 1 Month Change | -56.79% |
| 3 Month Change | -51.67% |
| 1 Year Change | -78.39% |
| 3 Year Change | -92.51% |
| 5 Year Change | -76.86% |
| Change since IPO | -61.04% |
Recent News & Updates
Recent updates
We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully
Mar 09
We're Not Very Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Rate
Oct 07NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans
May 23NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans
Feb 01We Think NextCell Pharma (STO:NXTCL) Can Afford To Drive Business Growth
Sep 21Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation
May 31We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully
Feb 15Shareholder Returns
| NXTCL | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -50.4% | 2.5% | -0.7% |
| 1Y | -78.4% | -3.4% | 4.4% |
Return vs Industry: NXTCL underperformed the Swedish Biotechs industry which returned -5.3% over the past year.
Return vs Market: NXTCL underperformed the Swedish Market which returned 10.3% over the past year.
Price Volatility
| NXTCL volatility | |
|---|---|
| NXTCL Average Weekly Movement | 16.0% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: NXTCL's share price has been volatile over the past 3 months.
Volatility Over Time: NXTCL's weekly volatility has increased from 11% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 17 | Mathias Svahn | www.nextcellpharma.com |
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank.
NextCell Pharma AB Fundamentals Summary
| NXTCL fundamental statistics | |
|---|---|
| Market cap | kr44.87m |
| Earnings (TTM) | -kr40.69m |
| Revenue (TTM) | kr15.64m |
2.9x
P/S Ratio-1.1x
P/E RatioIs NXTCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXTCL income statement (TTM) | |
|---|---|
| Revenue | kr15.64m |
| Cost of Revenue | kr11.42m |
| Gross Profit | kr4.22m |
| Other Expenses | kr44.91m |
| Earnings | -kr40.69m |
Last Reported Earnings
Nov 30, 2023
Next Earnings Date
Jul 25, 2024
| Earnings per share (EPS) | -1.18 |
| Gross Margin | 27.00% |
| Net Profit Margin | -260.20% |
| Debt/Equity Ratio | 0% |
How did NXTCL perform over the long term?
See historical performance and comparison